

AF/1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Steven R. Wiley

Serial No: 09/742,454

Filed: December 19, 2000

For: TWEAK RECEPTOR



Docket No.: 2968-B

Group Art Unit: 1642

Examiner: Yaen, C.H.

RESPONSE UNDER 37 C.F.R. § 1.116 **RECEIVED**

BOX AF
Commissioner for Patents
Washington, D.C., 20231

FEB 21 2003

TECH CENTER 1600/2900

Sir:

In response to the final Office Action ("the Action") mailed December 17, 2002 (Paper No. 15), and pursuant to 37 C.F.R. § 1.116, please consider the following remarks.

16/11c
(G)
2-2603

Applicant submits herewith:

- 1) *Appendix A*, presenting a copy of the pending claims; and
- 2) *Appendix B*, presenting a copy of Taylor *et al.*, 1999, Drug Discovery Today 4:562-67.

REMARKS

Claims 46-57 have not been rejected, therefore Applicant respectfully requests that Claims 46-57 be acknowledged as allowed.

The Action states that SEQ ID NO:2 of the instant Specification provides the amino acid sequence of the extracellular portion of the TWEAK receptor. Applicant respectfully points out that SEQ ID NO:2 provides the amino acid sequence of the entire TWEAK receptor.

I. The Rejections

A. Rejection of Claims 72-90 for Allegedly Being Indefinite Under 35 U.S.C. § 112, Second Paragraph

Claims 72-90 are rejected under 35 U.S.C. § 112, second paragraph, for allegedly being indefinite. Applicant respectfully traverses.

The Action states that: